Novo poised for Novoeight launch in hemophilia; United Health aims for leverage with PBM buyout;

@FiercePharma: Report: Pet owners clueless about obesity in their cats and dogs. FierceAnimalHealth item | Follow @FiercePharma

@EricPFierce: ICYMI: Genentech expansion adds to Roche biologics buildout. It promises 100 jobs, $125M outlay. Report | Follow @EricPFierce

@CarlyHFierce: $GSK finally seals U.K. Bexsero deal for £20 per dose. FierceVaccines story | Follow @CarlyHFierce

> Novo Nordisk ($NVO) plans to roll out its new hemophilia treatment Novoeight next month in the U.S. Release | Report

> United Health ($UNH) snapped up the pharmacy benefits manager Catamaran ($CTRX) for about $12.8 billion, in a move for better leverage in negotiating drug prices with pharma companies. Report

> European regulators postponed their approval decision on Bristol-Myers Squibb's ($BMY) Opdivo; a company spokeswoman told Reuters the company had submitted additional data on the med, triggering the delay. Report

> The latest of nearly five months of speculation has Panasonic Healthcare counting on paying only $830 million for Bayer's diabetes device business, from previous estimates of up to $2.3 billion. Report

> The European Commission gave its blessing to a German scheme allowing some drugs to be exempt from price freezes, provided companies could prove the pricing move put an unacceptable financial burden on them. Report

> West Virginia legislators repealed a law requiring drugmakers to report their spending on drug-brand advertising in the state. Report

> Generics makers launched a new challenge to the FDA's proposal to require them to update their own drug labels when health risks are discovered, rather than waiting for the branded drugmaker to make label changes. Report

Medical Device News

@FierceMedDev: Zimmer to divest three businesses to satisfy EU regulators in Biomet acquisition. Report | Follow @FierceMedDev

@VarunSaxena2: Outgoing FDA commissioner: Regulation, when done right, not a roadblock | National Press Club. More | Follow @VarunSaxena2

@EmilyWFierce: Horizon scoops up Hyperion and its rare disease portfolio for $1.1B. FiercePharma news | Follow @EmilyWFierce

> FDA taking 'very light touch' in smartphone and digital device regulation. Story

> Nanorobot shows promise as humidity sensor thanks to use of bacterial spore. Article

> Devicemaker, CEO, take on FDA over 'free speech' of sales pitch. More

Biotech News

@FierceBiotech: Skincare startup bags $50M to get its acne drug into Phase III. Story | Follow @FierceBiotech

@JohnCFierce: Big part of the $NVS/Aduro deal is that Dana Farber's Glenn Dranoff was tapped to run a new IO R&D group. More | Follow @JohnCFierce

@DamianFierce: Success for Sovaldi, a win for Vimizim and a eulogyto for Blincyto. #FierceMadness continues. More | Follow @DamianFierce

> BioDelivery tanks as its pain gel comes up short in Phase III. Story

> Merck KGaA forges a $941M CAR-T development deal with Intrexon. News

> Novartis tackles immuno-oncology with a $750M Aduro deal for new R&D group. Article

Animal Health News

> Jaguar Animal Health eyes a second run at IPO. Report

> Critics say White House plan to combat antibiotic resistance falls 'woefully short.' More

> Report: Pet owners clueless about obesity in their cats and dogs. Item

> Gene testing and animal safety services drive double-digit growth at Neogen. Article

> U.K. scientists discover parasite protects cows against deadly East Coast fever. Story

Biotech IT News

> George Church backs online platform for open sharing of personal data. Report

> Committee clips the wings of Europe's controversial $1B brain project. Article

> Emerging markets tipped to push drug safety software market past $150M. Story

> NIH backs database of rare pediatric genetic disorders. Item

> 100,000 Genomes Project taps Big Pharma dream team for data crunching skills. More

And Finally... Aetna ($AET) agreed to cut out-of-pocket costs for most HIV and AIDS drugs after patient advocates protested a big increase in co-insurance. Report

Suggested Articles

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.

Already developing coronavirus treatments, Takeda struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan

Pfizer struck a deal to produce Gilead Sciences' remdesivir, which has been running short at some hard-hit U.S. hospitals.